Measuring the burden of cystic fibrosis: A scoping review.

Autor: Cheema ZM; Department of Medicine, McMaster University, Hamilton, Canada; Cystic Fibrosis Canada, Toronto, Canada., Gomez LC; Department of Community Health, and Epidemiology, Faculty of Medicine, Dalhousie University, Halifax, Canada., Johnson N; Department of Community Health, and Epidemiology, Faculty of Medicine, Dalhousie University, Halifax, Canada., Laflamme OD; Department of Community Health, and Epidemiology, Faculty of Medicine, Dalhousie University, Halifax, Canada., Rabin HR; Department of Medicine, Cumming School of Medicine at the University of Calgary, Calgary, Canada., Steele K; Cystic Fibrosis Canada, Toronto, Canada., Wallenburg J; Cystic Fibrosis Canada, Toronto, Canada., Leong J; Department of Medicine, Cumming School of Medicine at the University of Calgary, Calgary, Canada., Cheng SY; Cystic Fibrosis Canada, Toronto, Canada., Quon BS; Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, Canada., Stephenson AL; Division of Respirology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada., Wranik WD; Department of Community Health, and Epidemiology, Faculty of Medicine, Dalhousie University, Halifax, Canada; Department of Public and International Affairs, Faculty of Management, Dalhousie University, Halifax, Canada., Sadatsafavi M; Respiratory Evaluation Sciences Program, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada., Stanojevic S; Department of Community Health, and Epidemiology, Faculty of Medicine, Dalhousie University, Halifax, Canada. Electronic address: Sanja.Stanojevic@dal.ca.
Jazyk: angličtina
Zdroj: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society [J Cyst Fibros] 2024 Sep; Vol. 23 (5), pp. 823-830. Date of Electronic Publication: 2023 Dec 03.
DOI: 10.1016/j.jcf.2023.11.014
Abstrakt: Background: Cystic fibrosis (CF) contributes a significant economic burden on individuals, healthcare systems, and society. Understanding the economic impact of CF is crucial for planning resource allocation.
Methods: We conducted a scoping review of literature published between 1990 and 2022 that reported the cost of illness, and/or economic burden of CF. Costs were adjusted for inflation and reported as United States dollars.
Results: A total of 39 studies were included. Direct healthcare costs (e.g., medications, inpatient and outpatient care) were the most frequently reported. Most studies estimated the cost of CF using a prevalence-based (n = 18, 46.2 %), bottom-up approach (n = 23, 59 %). Direct non-healthcare costs and indirect costs were seldom included. The most frequently reported direct cost components were medications (n = 34, 87.2 %), inpatient care (n = 33, 84.6 %), and outpatient care (n = 31, 79.5 %). Twenty-eight percent (n = 11) of studies reported the burden of CF from all three perspectives (healthcare system (payer), individual, and society). Indirect costs of CF were reported in approximately 20 % of studies (n = 8). The reported total cost of CF varied widely, ranging from $451 to $160,000 per person per year (2022 US$). The total cost depended on the number of domains and perspectives included in each study.
Conclusions: Most studies only reported costs to the healthcare system (i.e., hospitalizations and healthcare encounters) which likely underestimates the total costs of CF. The wide range of costs reported highlights the importance of standardizing perspectives, domains and costs when estimating the economic burden of CF.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2023. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: